Phuturdex › Drugs › Elraglusib
Drugs in development · updated 11 November 2026
Elraglusib: clinical trials and development status
Other names and codes: 9-ING-41
As of 11 November 2026 Elraglusib is in 5 active clinical trials (recruiting or ongoing, phases I–III) for 15 diseases. The most advanced phase is II.
Authorisation
- EU no (EMA)
- Italy not in the AIFA register
- Germany not available
- US no (FDA)
Sources: EMA, AIFA register (open data), FDA. For Germany only the EU centralised authorisation is shown: the national BfArM register is not one of our sources.
Map of sites in Europe with recruitment status, every trial and an email when something changes. Full access free until 31 March 2027, no card needed.
What it is
A maleimide-based, small molecule inhibitor of glycogen synthase kinase-3 (GSK-3; serine/threonine-protein kinase GSK3) with potential antineoplastic activity. Upon intravenous administration, elraglusib binds to and competitively inhibits GSK-3, which may lead to downregulation of nuclear factor kappa B (NF-kappaB) and decreased expression of NF-kappaB target genes including cyclin D1, B-cell lymphoma 2 (Bcl-2), anti-apoptotic protein XIAP, and B-cell lymphoma extra-large (Bcl-XL). This may inhibit NF-kappaB-mediated survival and chemoresistance in certain tumor types. GSK-3, a constitutively active serine/threonine kinase that plays a role in numerous pathways involved in protein synthesis, cellular proliferation, differentiation, and metabolism, is aberrantly overexpressed in certain tumor types and may promote tumor cell survival and resistance to chemotherapy and radiotherapy.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Metastasis | II | 2 | NCT05010629 |
| Adenoid cystic carcinoma | II | 1 | NCT05010629 |
| Adult T-cell leukemia/lymphoma | II | 1 | NCT03678883 |
| Bone neoplasm | II | 1 | NCT03678883 |
| Breast neoplasm | II | 1 | NCT03678883 |
| Colorectal neoplasm | II | 1 | NCT03678883 |
| Glioma | II | 1 | NCT03678883 |
| Kidney neoplasm | II | 1 | NCT03678883 |
| Lung neoplasm | II | 1 | NCT03678883 |
| Neoplasm | II | 1 | NCT03678883 |
| Non-Hodgkin lymphoma | II | 1 | NCT03678883 |
| Pancreatic neoplasm | II | 1 | NCT03678883 |
| Salivary gland neoplasm | II | 1 | NCT05010629 |
| Sarcoma | II | 1 | NCT03678883 |
| Hereditary sensory and autonomic neuropathy | I | 1 | NCT06896188 |
Sites in Europe
20 sites of the active trials in 5 European countries, 0 recruiting.
- France7
- Spain5
- Belgium4
- Portugal3
- Netherlands1
Sites declared by the sponsors on ClinicalTrials.gov; region worked out by Phuturdex from the geographic point. The list of sites with city and recruitment status is in the app. See the sites →
Everything on Elraglusib
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 11 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, refers to the United States and is a Phuturdex calculation described on the Method page, not official data: the drug may already be marketed in other countries.